COPD
-
Effects of LAMA or ICS withdrawal may increase risk for COPD exacerbations
Discontinuing LAMA or ICS treatment may more than double the risk of exacerbations for up to 90 days, according to an analysis by Alexander Mathioudakis, MD, PhD.
-
RSV hospitalization increases cardiorespiratory event, COPD exacerbation risk
Caihua Liang, MD, PhD, and Elizabeth Begier, MD, discuss the importance of prevention in light of data showing elevated risk for up to 180 days following the acute infection.
-
GLP-1RAs may trigger chronic cough for some patients with diabetes
Surprisingly, the association between GLP-1 medications and chronic cough was stronger in patients without an existing diagnosis of gastroesophageal reflux disease.
-
Optimal synergy: Coupling smart wearable devices, sensors with AI algorithms
Coupling noninvasive wearable devices with AI-enabled data analytics helps to address two key challenges: health care access and improvement of patient-centric care.
-
2026 GOLD report provides key updates on COPD exacerbations, case finding
Gerard J. Criner, MD, FCCP, a member of the GOLD Science Committee, said the latest insights aim to improve patient outcomes and bring awareness to treating COPD exacerbations.
-
AI-enabled approaches poised to transform diagnosis, management of lung diseases
Experts explore how AI-based tools can be used to bridge diagnostic challenges and address unmet needs in chronic respiratory disease care.
-
Patients with COPD, bronchiectasis experience sex-based disparities in care
Radmila Choate, PhD, MPH, and her team sought to capture “lived experiences in a way that helps clinicians recognize patterns that differ for women and men and adapt care more thoughtfully.”
-
Mucus plug gene expression could identify new COPD targets
Recent research has identified distinct gene clusters that may underly the clinical heterogeneity of mucus pathology and inform further studies, investigator Ehab Billatos, MD, said.
-
CMS releases updated guidance for NIPPV in patients with COPD
Understand the new CMS guidance, which comes after more than a decade of strategic advocacy efforts led by CHEST.
-
The climate cost of inhalers: What prescribers should know
Experts said clinicians must ensure patients have the therapies they need at affordable prices that, ideally, impose minimal amounts of environmental harm.
